RLS Global AB Interim Report Q2, 2019

April 1st - June 30th

  •  Net sales amounted to SEK 0.5 million (0.4), a revenue growth of 25 percent
  •  Earnings before interest and taxes (EBIT) amounted to SEK -5.8 million (-6.3)
  •  Earnings per share after dilution at SEK -0.10 (-0.11)
  •  Cash flow from operating activities amounted to SEK -6.3 million (-4.9)
  •  Liquid assets at the end of the period at SEK 8.3 million (34.5)
  •  Equity ratio was 82 percent (86)

January 1st - June 30th

  • Net sales amounted to SEK 0.7 million (0.5), a revenue growth of 38 percent
  • Earnings before interest and taxes (EBIT) amounted to SEK -11.6 million (-11.1)
  • Earnings per share after dilution at SEK -0.20 (-0.19)
  • Cash flow from operating activities amounted to SEK -11.8 million (-10.8)
  • Liquid assets at the end of the period at SEK 8.3 million (34.5)
  • Equity ratio was 82 percent (86)

Summary of events during second quarter 

  • ChloraSolv receives CE marking and is cleared for commercial launch in EU
  • RLS Global AB has reached a settlement with Dr. Karin Bergqvist
  • During June 5-7, the EWMA Conference (European Wound Management Association) took place in Gothenburg
  • The clinical trial in Sweden on ChloraSolv 01 is running according to plan
  • ChloraSolv registration for Australia initiated

Summary of events after second quarter

  •  A product specialist joined in August and will drive the ChloraSolv commercialization process for the Swedish market
  •  Meetings with several Key Opinion Leaders to introduce the benefits of ChloraSolv
  •  Continuous negotiations with potential global partners
  •  Extra General Meeting will be held August 19th 

Trading place and certified advisor 
RLS Global’s shares has been listed on the Nasdaq First North since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Erik Penser Bank, telephone +46 8 463 83 00, Email: certifiedadviser@penser.se. 

During the period 2012 - 2017, the company was listed on Aktietorget.

Contact information 
Karin Fischer, CEO
E-mail: karin.fischer@rlsglobal.se 
Telephone: +46 702 48 46 51

Eva Jagenheim, CFO
E-mail: eva.jagenheim@rlsglobal.se
Telephone: +46 31 780 68 20 

The interim report is enclosed and is also available at www.rls.global

Publication 

RLS Global AB (publ) is obliged to make the information contained herein public pursuant to the EU market abuse regulation. The information was submitted for publication through the agency of the above contact person, at 08:30 CET on August 15th, 2019.

About RLS Global
For more than 20 years, RLS Global has worked with Oral Care specialists, pioneering new therapies for Oral Care and their patients. We are now taking another major step toward easier and more effective care within Wound Care. We will continue to work with Health care Professionals to ensure to develop a treatment that further helps deliver the best care for each patient. The method is clinically proven and saves the patient a lot of suffering. Our focus is on caring for the patients, developing efficient and safe products that offer gentle treatment methods. We’re proud to provide Minimally Invasive Therapy which provides Quality of Life for patients worldwide.

Om oss

RLS Global AB har samarbetat med specialister inom tandvård sedan många år tillbaka, utvecklat och lanserat innovativa lösningar för tandvårdspatienter. Vi har nu tagit ytterligare ett steg inom företaget och breddat vårt erbjudande genom att bygga upp ett nytt affärsområde – sårvård. Vi kommer att fortsätta att samarbeta med sjukvårdspersonal för att utveckla en behandling som hjälper till att leverera den bästa vården för varje patient. Behandlingen är kliniskt bevisad och sparar patienten mycket lidande. Vårt fokus ligger på att ta hand om patienter samt utveckla säkra och effektiva produkter som erbjuder skonsamma behandlingsmetoder. Vi är stolta över att kunna erbjuda minimalinvasiv behandling och förbättra livskvaliteten för patienter över hela världen.